Q-omics provides the consensus-scored FAM72D profile across patient tissues and cancer cell-line models. FAM72D expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FAM72D is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, FAM72D RNA expression shows 18,973 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, BLCA, and LSCC as cancer lineages where FAM72D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM72D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM72D survival associations across molecular data types. FAM72D RNA expression shows survival associations in the most cancer types (28). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM72D RNA expression–survival associations across cancer types. High FAM72D expression shows unfavorable associations in ACC, KIRC, KIRP, MESO, KICH and UVM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for FAM72D RNA expression.
This table summarizes FAM72D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM72D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM72D shows higher tumor expression in BLCA, HNSC, LUAD, COAD, KIRC and STAD. The BLCA box plot shows higher FAM72D RNA expression in tumor versus normal tissue (log2 FC = +1.428, t-test p < 0.001).
This table shows molecular features associated with FAM72D in patient tissues and cancer cell lines. In patient samples, FAM72D shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM72D RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma.
